Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ImmuneID.

    Client Virtual Booth

    IMMUNEID

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ImmuneID
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    650 East Kendall St, 2nd Floor Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immuneidrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immuneid/
    Twitter
    Twitter
    https://twitter.com/immuneid

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

    Details:

    Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases including GLM101.


    Lead Product(s): GLM101

    Therapeutic Area: Rare Diseases and Disorders Product Name: GLM101

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Glycomine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Series B Financing June 23, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

    Details:

    Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Alta Partners

    Deal Size: $70.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing June 23, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search